RFL News and Press, Rafael Holdings Inc. Class B From 10/28/21

Phase 3 Clinical Trial in Metastatic Pancreatic Cancer Did Not Meet its Primary Endpoint of Improved Overall Survival Independent Data Monitoring Committee Recommended the Phase 3 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia Be Stopped Due to Lack of Efficacy ...

NEWARK, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), announced that today it made a grant to Dr. Mary Margaret Huizinga of options to purchase 122,341 shares of Class B common stock of the Company with an exercise price equal to $30.54, the closing price ...

We expect Rafael Pharmaceuticals to report top line data from its AVENGER 500 Phase 3 registrational clinical trial in metastatic pancreatic cancer this calendar year We expect to submit our previously announced merger with Rafael Pharmaceuticals to our stockholders for a vote t...

Gainers: Voyager Therapeutics (NASDAQ:VYGR) +57%, Acer Therapeutics (NASDAQ:ACER) +9%, Molecular Partners (NASDAQ:MOLN) +10%, Rafael (NYSE:RFL) +6%, Arcturus Therapeutics (NASDAQ:ARCT) +7%. Losers: Ginkgo Bioworks (NYSE:DNA) -21%, OpGen (...

Rafael Holdings Appoints Mimi Huizinga, MD, MPH as Chief Development and Medical Officer PR Newswire NEWARK, N.J. , Oct. 6, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical holding company focused on developing novel cancer metabolism...

CRANBURY, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced that the Phase 1 clinical trial of CPI-613® (devimistat) in comb...

Rafael Holdings (NYSE:RFL) has appointed Ashok Marin chief legal officer. Marin was previously vice president, deputy general counsel, chief compliance officer and chief privacy officer at Immunomedics. In June, Rafael Pharmaceuticals, which Rafael Holdings is a majority shareholder in, recei...

Rafael Holdings Appoints Patrick Fabbio as Chief Financial Officer PR Newswire NEWARK, N.J. , Sept. 14, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics throu...

NEW YORK, NY / ACCESSWIRE / September 1, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Rafael Holdings, Inc. (NYSE:RFL) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...

Insider buying increased last week. Chief Executive Officer Howard S. Jonas purchases $5 million worth of shares of Rafael Holdings, Inc. Director Terry Considine continues to buy shares of Apartment Investment and Management Company. For further details see: Insider Wee...